Exelixis: FDA Approval for Cabometyx in Combination with Opdivo
Exelixis (EXEL) announced that the United States FDA has approved CABOMETYX (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for patients with advanced renal cell carcinoma (RCC).
RCC is among the 10 most frequently diagnosed cancers in the U.S. annually.
Dr. Toni Choueiri, Director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute and The Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School, said, “The combination of cabozantinib and nivolumab significantly improved progression-free survival, overall survival, and objective response rate while showing a low rate of treatment discontinuations due to side effects compared to sunitinib. The therapeutic benefit demonstrated in CheckMate -9ER and quality of life measures explored emphasize the role of this combination for patients with advanced kidney cancer. “With this important FDA approval, the combination is poised to become a standard in newly diagnosed metastatic kidney cancer.”